S † Nam side by side		Hit Count S	t Nam
DB=USF	PT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR		
<u>L7</u>	(OMV or outer adj membrane adj vesicle\$) same immune adj enhanc\$	2	<u>L7</u>
<u>L6</u>	(OMV or outer adj membrane adj vesicle\$) same immune adj stimulant\$	0	<u>L6</u>
<u>L5</u>	(OMV or outer adj membrane adj vesicle\$) same immunostimulant\$	0	<u>L5</u>
<u>L4</u>	L3 same mening\$	14	<u>L4</u>
<u>L3</u>	OMV or outer adj membrane adj vesicle\$ same immunostimulant\$	219	<u>L3</u>
<u>L2</u>	L1 same conjugat\$	9	<u>L2</u>
<u>L1</u>	OMV or outer adj membrane adj vesicle\$ same adjuvant\$	227	<u>L1</u>

END OF SEARCH HISTORY

annuman	waaaaaaaaaaaaaaaaa WEST			simumis.
	Help Logout Interrupt			
Main Menu	Search Form Posting Counts Show S Numbers Edit S Numbers	Prefer	ences	Cases

	Search Results -			
	Terms Documents			
	L1 and OMP 2			
***************************************		••••••		
Database:	US Patents Full-Text Database US Pre-Grant Publication Full-Text Database JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins			
Search:	L2		Refine	Search
	Recall Text Clear			
	Search History			
DATE: F	riday, March 14, 2003 Printable Copy Create C	<u>ase</u>		
S † Name side by side	Query	Hit Co		et Name
DB=USI	PT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR			
<u>L2</u>	L1 and OMP		2	<u>L2</u>
<u>L1</u>	mening\$ adj5 C same oligosacchar\$ same conjugat\$		17	<u>L1</u>
5115 OF 5				

END OF SEARCH HISTORY

Generate Collection

Print

Search Results - Record(s) 1 through 10 of 17 returned.

1. Document ID: US 20010048929 A1

L1: Entry 1 of 17

File: PGPB

Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010048929

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010048929 A1

TITLE: NOVEL MULTI-OLIGOSACCHARIDE GLYCOCONJUGATE BACTERIAL MENINGITIS

VACCINES

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

CHONG, PELE

RICHMOND HILL

CA

LINDBERG, ALF

LYON

FR

KLEIN, MICHEL

WILLOWDALE

CA

US-CL-CURRENT: 424/234.1; 424/236.1, 424/244.1, 424/249.1

ull Title	e Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC
Drawi Desc Ir	Image									

2. Document ID: US 6413520 B1

L1: Entry 2 of 17

File: USPT

Jul 2, 2002

US-PAT-NO: 6413520

DOCUMENT-IDENTIFIER: US 6413520 B1

TITLE: Methods of immunizing adults using anti-meningococcal vaccine compositions

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draws Description

3. Document ID: US 6403099 B1

L1: Entry 3 of 17

File: USPT

Jun 11, 2002

US-PAT-NO: 6403099

DOCUMENT-IDENTIFIER: US 6403099 B1

TITLE: Conjugates formed from heat shock proteins and oligo-or polysaccharides

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC |
Draw, Desc | Image |

4. Document ID: US 6251401 B1

L1: Entry 4 of 17

File: USPT

Jun 26, 2001

US-PAT-NO: 6251401

DOCUMENT-IDENTIFIER: US 6251401 B1

TITLE: Combined meningitis vaccine



5. Document ID: US 6168796 B1

L1: Entry 5 of 17

File: USPT

Jan 2, 2001

US-PAT-NO: 6168796

DOCUMENT-IDENTIFIER: US 6168796 B1

TITLE: Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw Desc Image

6. Document ID: US 6132723 A

L1: Entry 6 of 17


File: USPT

Oct 17, 2000

US-PAT-NO: 6132723

DOCUMENT-IDENTIFIER: US 6132723 A

TITLE: Immunogenic oligosaccharide compositions



L1: Entry 10 of 17

File: USPT

Sep 15, 1998

US-PAT-NO: 5807553

DOCUMENT-IDENTIFIER: US 5807553 A

TITLE: Immonogenic oligosaccharide compositions

Generate Collection Print Terms	aw. Desc Image	ont Review Classification		Attachments	
Generate Collection Print			10		
Terms			 rint		

		Terms	 	Documents	

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection

Print

Search Results - Record(s) 11 through 17 of 17 returned.

11. Document ID: US 5695768 A

L1: Entry 11 of 17

File: USPT

Dec 9, 1997

US-PAT-NO: 5695768

DOCUMENT-IDENTIFIER: US 5695768 A

TITLE: Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

KWIC

12. Document ID: US 4711779 A

L1: Entry 12 of 17

File: USPT

Dec 8, 1987

US-PAT-NO: 4711779

DOCUMENT-IDENTIFIER: US 4711779 A

TITLE: Glycoproteinic conjugates having trivalent immunogenic activity

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

KrúáC

13. Document ID: US 4356170 A

L1: Entry 13 of 17

File: USPT

Oct 26, 1982

US-PAT-NO: 4356170

DOCUMENT-IDENTIFIER: US 4356170 A

TITLE: Immunogenic polysaccharide-protein conjugates

Full Title Citation Front Review Classification Date Reference Sequences Attachments
Draw, Desc Image

KONAC

14. Document ID: WO 9942130 A1

L1: Entry 14 of 17

File: EPAB

Aug 26, 1999

PUB-NO: WO009942130A1

DOCUMENT-IDENTIFIER: WO 9942130 A1

TITLE: MULTI-OLIGOSACCHARIDE GLYCOCONJUGATE BACTERIAL MENINGITIS VACCINES

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

15. Document ID: WO 9317712 A2

L1: Entry 15 of 17

File: EPAB

Sep 16, 1993

PUB-NO: WO009317712A2

DOCUMENT-IDENTIFIER: WO 9317712 A2

TITLE: CONJUGATES FORMED FROM HEAT SHOCK PROTEINS AND OLIGO- OR POLYSACCHARIDES



16. Document ID: WO 9961053 A1 JP 2002516292 W AU 9942215 A BR 9910749 A EP 1079857 A1

L1: Entry 16 of 17

File: DWPI

Dec 2, 1999

DERWENT-ACC-NO: 2000-097070

DERWENT-WEEK: 200239

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Immunogenic composition for the prevention and treatment of diseases caused by serogroups B and C strains of Neisseria meningitidis



	17.	Document ID:	WO 9614086	A1 US	6251401	B1 EP	789587	A1 JP
1050	9701	W						

L1: Entry 17 of 17

File: DWPI

May 17, 1996

DERWENT-ACC-NO: 1996-251554

DERWENT-WEEK: 200138

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Combined vaccine against meningitis contg. <u>oligosaccharide conjugates</u> - of Haemophilus influenzae and Neisseria <u>meningitidis serotype C.</u>

	Generate Collection	Print	
--	---------------------	-------	--

Display Format: -

Change Format

<u>Previous Page</u>

Next Page

Generate Collection Print

L4: Entry 11 of 14

File: DWPI

May 7, 2002

DERWENT-ACC-NO: 2002-436218

DERWENT-WEEK: 200247

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Meningitis type B and C vaccine comprises meningococcus outer membrane vesicles as an antigen

for polysaccharide matter

INVENTOR: FUKASAWA, LO; OUTEIRO GORLA, MC; RAW, I; SCHENKMAN, RPF; TANIZAKI, MM

PATENT-ASSIGNEE:

ASSIGNEE

CODE

FUKASAWA L O

FUKAI

FUNDACAO BUTANTAN

BUTAN

OUTEIRO GORLA M C

GORLI

SCHENKMAN R P F

SCHEI

TANIZAKI M M

TANII

PRIORITY-DATA: 2000BR-0004568 (August 29, 2000)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

BR 200004568 A

May 7, 2002

001

A61K039/095

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

BR 200004568A

August 29, 2000

2000BR-0004568

INT-CL (IPC): A61 K 39/095; A61 P 31/04

ABSTRACTED-PUB-NO: BR 200004568A

BASIC-ABSTRACT:

NOVELTY - A <u>meningitis</u> type B and C vaccine comprising PS C (capsular polysaccharide serum group C) and outer membrane vesicules (OMV) of meningococcus serum group B.

An INDEPENDENT CLAIM is also included for producing the vaccine, using the capacity of the OMV to charge the PS $\mathcal C$ and as an antigen for the serum group $\mathcal B$.

USE - A vaccine for meningitis type B and C.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: MENINGITIS TYPE VACCINE COMPRISE MENINGOCOCCUS OUTER MEMBRANE VESICLE ANTIGEN POLYSACCHARIDE MATTER

DERWENT-CLASS: BO4 D16

CPI-CODES: B04-B04C1; B04-C02F; B14-A01A5; B14-S11B; D05-H07;

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2002-123987

End of R sult S t

Generate Collection Print

L4: Entry 14 of 14

File: DWPI

Apr 14, 1994

DERWENT-ACC-NO: 1994-135585

DERWENT-WEEK: 199810

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New B cell activating molecules from meningococcal lipo:polysaccharide - and derived peptide conjugates, outer membrane vesicles etc. useful in vaccines effective against several meningococcal immunotypes.

INVENTOR: HOOGERHOUT, P; POOLMAN, J T; VAN DER LEY, P A

PATENT-ASSIGNEE:

ASSIGNEE CODE NEDERLANDEN MIN WELZIJN **NEWEN** STAAT NEDERLANDEN MIN VAN WELZIJN **NEWEN**

PRIORITY-DATA: 1992NL-0001716 (October 2, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9408021 A1	April 14, 1994	E	062	C12N015/61
AU 684720 B	January 8, 1998		000	C08B037/00
NL 9201716 A	May 2, 1994		000	A61K047/48
AU 9348351 A	April 26, 1994		000	C12N015/61
NO 9501181 A	June 1, 1995		000	C12N000/00
FI 9501535 A	June 1, 1995		000	A61K000/00
EP 680512 A1	November 8, 1995	E	000	C12N015/61
JP 08501940 W	March 5, 1996		076	C12N015/09
US 5705161 A	January 6, 1998		024	A61K039/095

DESIGNATED-STATES: AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

CITED-DOCUMENTS:6.Jnl.Ref; NL 9101359; WO 9006696

APPLICATION-DATA:			
PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9408021A1	July 30, 1993	1993WO-NL00163	
AU 684720B	July 30, 1993	1993AU-0048351	
AU 684720B		AU 9348351	Previous Publ.
AU 684720B		WO 9408021	Based on
NL 9201716A	October 2, 1992	1992NL-0001716	
AU 9348351A	July 30, 1993	1993AU-0048351	•
AU 9348351A		WO 9408021	Based on
NO 9501181A	July 30, 1993	1993WO-NL00163	
NO 9501181A	March 28, 1995	1995NO-0001181	
FI 9501535A	July 30, 1993	1993WO-NL00163	
FI 9501535A	March 31, 1995	1995FI-0001535	
EP 680512A1	July 30, 1993	1993EP-0921120	
EP 680512A1	July 30, 1993	1993WO-NL00163	
EP 680512A1		WO 9408021	Based on
JP 08501940W	July 30, 1993	1993WO-NL00163	
JP 08501940W	July 30, 1993	1994JP-0508917	
JP 08501940W		WO 9408021	Based on
US 5705161A	July 30, 1993	1993WO-NL00163	
US 5705161A	May 1, 1995	1995US-0411727	•
US 5705161A		WO 9408021	Based on

INT-CL (IPC): A61 K 0/00: A61 K 39/00; A61 K 39/095; A61 K 45/00; A61 K 47/48; C07 H 1/00; C07 K 9/00; C07 K 14/195; C07 K 15/00; C08 B 37/00; C12 N 0/00; C12 N 1/21; C12 N 15/00; C12 N 15/09; C12 N 15/31; C12 N 15/61; C12 N 15/62; C12 P 19/04; C12 P 19/34; C12 N 1/21; C12 R 1:36; C12 N 1/21; C12 R 1:36

ABSTRACTED-PUB-NO: US 5705161A BASIC-ABSTRACT:

New immunity-providing B-cell activating molecule (A) derived from meningococcal lipopolysaccharide (LPS) with at least one epitope, comprises at least the communal part of the oligosaccharide (core region) of LPS specific for at least 2 meningococcal immunotypes (pref. L2 and L3) with galactose absent from the B-cell activating part. Also included are derivs. of (A) with immune-reaction inducing activity.

Also new are (1) saccharide-peptide conjugates (SPC) contg. (A) as saccharide component conjugated to a peptide part having at least one T helper cell activating epitope; (2) outer membrane vesicles (OMV) contg. (A) and/or SPC; (3) OMV having a gp. of polypeptides with immunoactivity of outer membrane proteins (OMP) bound to a membrane, at least one of these having a mutation in a surface loop; (4) nucleic acid encoding recombinant OM1 (or fragments) carrying such a mutation; (5) expression vectors contg. this nucleic acid; (6) microorganism contg. such nucleic acid or vectors; (7) OMP-derived polypeptides which have a surface loop mutation; (8) nucleic acid encoding LPS that differs from wild type in having a mutation causing expression of no (functional) galE; (9) expression

vectors and microorganisms contg. this nucleic acid; (10) mutated <u>meningococcal</u> strains that produce galactose-free LPS or no functional galE.

USE/ADVANTAGE <u>- OMV</u>, SPC, the nucleic acids, expression vectors, transformed cells and polypeptides are all useful in vaccines to protect against gp. B <u>meningococci</u>. (A) represent small B-cell activating molecules that are easy to obtain, non-toxic and able to induce immunity against several immunotypes. Insertion of mutations in surface loops allows attachment of the saccharide component without altering the tert. structure (immunogenicity) of the saccharide.

ABSTRACTED-PUB-NO:

WO 9408021A
EQUIVALENT-ABSTRACTS:

New immunity-providing B-cell activating molecule (A) derived from meningococcal lipopolysaccharide (LPS) with at least one epitope, comprises at least the communal part of the oligosaccharide (core region) of LPS specific for at least 2 meningococcal immunotypes (pref. L2 and L3) with galactose absent from the B-cell activating part. Also included are derivs. of (A) with immune-reaction inducing activity.

Also new are (1) saccharide-peptide conjugates (SPC) contg. (A) as saccharide component conjugated to a peptide part having at least one T helper cell activating epitope; (2) outer membrane vesicles (OMV) contg. (A) and/or SPC;(3) OMV having a gp. of polypeptides with immunoactivity of outer membrane proteins (OMP) bound to a membrane, at least one of these having a mutation in a surface loop; (4) nucleic acid encoding recombinant OM1 (or fragments) carrying such a mutation; (5) expresion vectors contg. this nucleic acid; (6) microorganism contg. such nucleic acid or vectors; (7) OMP-derived polypeptides which have a surface loop mutation; (8) nucleic acid encoding LPS that differs from wild type in having a mutation causing expression of no (functional) galE; (9) expression vectors and microorganisms contg. this nucleic acid; (10) mutated meningococcal strains that produce galactose-free LPS or no functional galE.

USE/ADVANTAGE <u>- OMV</u>, SPC, the nucleic acids, expression vectors, transformed cells and polypeptides are all useful in vaccines to protect against gp. B <u>meningococci</u>. (A) represent small B-cell activating molecules that are easy to obtain, non-toxic and able to induce immunity against several immunotypes. Insertion of mutations in surface loops allows attachment of the saccharide component without altering the tert. structure (immunogenicity) of the saccharide.

CHOSEN-DRAWING: Dwg.0/0 Dwg.0/0

TITLE-TERMS: NEW CELL ACTIVATE MOLECULAR MENINGOCOCCUS LIPO POLYSACCHARIDE DERIVATIVE PEPTIDE CONJUGATE OUTER MEMBRANE VESICLE USEFUL VACCINE EFFECT MENINGOCOCCUS

DERWENT-CLASS: BO4 D16

CPI-CODES: B04-C01; B04-C02F; B04-C02V; B04-C02X; B04-E02F; B04-E08; B04-F10A5E; B04-N03; B04-N04; B14-G01; B14-S11B; D05-C12; D05-H07; D05-H10; D05-H12B2; D05-H12E; D05-H14A1; D05-H17B5;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
M423 M710 M903 P210 P220 Q233 V288 V500 V540 V735
V753 V901 V917

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1994-062771

	annananananananananananananananananana
Help Logout Interrupt	
Main Menu Search Form Posting Counts Show S Numbers Edit S Numbers Preference	es Cases
Search Results -	
Terms	Documents
(OMV or outer adj membrane adj vesicle\$) same immune adj enhanc\$	2
US Patents Full-Text Database US Pre-Grant Publication Full-Text Database JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins Δ Δ Δ Δ Δ Δ Δ Δ	
Search: Recall Text Clear	efine Search
Search History	

DATE: Friday, March 14, 2003 Printable Copy Create Case